Conformation-X Therapeutics, a Canton, MA-based immune-oncology focused drug development company, raised a further tranche of funding of $3.65M.
The round, which brought the total amount to $13.5M, saw participation from undisclosed investors.
The company intends to use the funds to accelerate its translational studies of its lead asset and facilitate the expansion of its pipeline.
Led by CEO Dr. Ali H. Munawar, Conformation-X Therapeutics utilizes a proprietary discovery platform enriched by structural insights to create therapeutics with innovative mechanisms of action. It is developing a diverse portfolio of immunotherapies that activate both the innate and adaptive arms of the immune system.
The company unveiled its lead assets by disclosing successful ex vivo and in vivo proof-of-concept studies for its HHLA2 and IL18BP programs, marking critical milestones in the cancer drug development process.